Printer Friendly

CAMBRIDGE NEUROSCIENCE NAMES CO-INVENTOR OF TAGAMET SENIOR DIRECTOR OF CHEMISTRY

CAMBRIDGE NEUROSCIENCE NAMES CO-INVENTOR OF TAGAMET SENIOR
 DIRECTOR OF CHEMISTRY
 CAMBRIDGE, Mass., March 26 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that it has named Graham Durant, Ph.D., a co-inventor of Tagamet(R), senior director of medicinal chemistry for the company.
 From 1960-1986, Dr. Durant served in a variety of research posts at SmithKline & French. From 1975 until 1985, he was head of medical chemistry at SmithKline and directed the histamine research programs. In 1989, Dr. Durant founded the Center for Drug Design and Development at the University of Toledo, Ohio, U.S.A., and has served as Distinguished Professor of Medicinal Chemistry at the University of Toledo since 1987.
 In recognition of his role in the discovery of Tagamet, Dr. Durant was inducted into the Inventor's Hall of Fame in 1990. He is the author or co-author of over 70 research publications and is named inventor or co-inventor of over 100 U.S. Patents.
 "We are extremely pleased to have Graham on board," stated Alan Dalby, chairman and chief executive officer of Cambridge NeuroScience. "Not only does he bring broad experience in chemistry, but an in-depth knowledge of receptor technology, and significant pharmaceutical industry research experience."
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders. The company's product development efforts are focused in three areas: neuroprotective compounds for the treatment of acute neurological disorders such as stroke and traumatic brain injury; novel antipsychotic compounds for the treatment of mental illnesses such as schizophrenia; and growth factors for the treatment of neurodegenerative diseases such as diabetic peripheral neuropathies and amytrophic lateral sclerosis (Lou Gehrig's disease).
 -0- 3/26/92
 /CONTACT: John T. Smith of Cambridge NeuroScience, 617-225-0600 ext. 151/
 (CNSI) CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU: PER


EG -- NE002 -- 1882 03/26/92 10:27 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 26, 1992
Words:319
Previous Article:BFS BANKORP ANNOUNCES MULTIFAMILY LOAN SECURITIZATION COMPLETION
Next Article:H.J. HEINZ COMPANY ANNOUNCES PROPOSED DEBT OFFERING
Topics:


Related Articles
CEPHALON APPOINTS NEW SCIENCE ADVISORY BOARD MEMBER
CAMBRIDGE NEUROSCIENCE APPOINTS TWO KEY SCIENTISTS
CYTOMED, INC. EXPANDS SCIENTIFIC TEAM -- ADDS SENIOR DIRECTOR, MEDICINAL CHEMISTRY AND PRINCIPAL SCIENTIST
CAMBRIDGE NEUROSCIENCE, INC. APPOINTS EDWARD S. CAMPANARO CLINICAL TRIALS MANAGER
ROBERT MCBURNEY PH.D., PROMOTED TO CHIEF SCIENTIFIC OFFICER, SENIOR VP RESEARCH FOR CAMBRIDGE NEUROSCIENCE, INC.
ELKAN GAMZU, PH.D. SUCCEEDS ALAN J. DALBY AS CHIEF EXECUTIVE OFFICER OF CAMBRIDGE NEUROSCIENCE; DALBY TO RETIRE AS CHAIRMAN IN MAY 1994
CAMBRIDGE NEUROSCIENCE, INC. APPOINTS FORMER MERCK RESEARCH LABORATORIES DIRECTOR AS VP, CLINICAL DEVELOPMENT
CAMBRIDGE NEUROSCIENCE NAMES NANCY AMER TO BOARD OF DIRECTORS
CAMBRIDGE NEUROSCIENCE NAMES BURKHARD BLANK, M.D. TO BOARD OF DIRECTORS
NitroMed Promotes David S. Garvey, Ph.D., to Senior Director of Chemistry and S. William Tam, Ph.D., to Senior Director of Biology

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters